WO2004110361A3 - Anticancer compositions comprising methenamine - Google Patents

Anticancer compositions comprising methenamine Download PDF

Info

Publication number
WO2004110361A3
WO2004110361A3 PCT/US2004/016455 US2004016455W WO2004110361A3 WO 2004110361 A3 WO2004110361 A3 WO 2004110361A3 US 2004016455 W US2004016455 W US 2004016455W WO 2004110361 A3 WO2004110361 A3 WO 2004110361A3
Authority
WO
WIPO (PCT)
Prior art keywords
methenamine
anticancer compositions
compositions
anticancer
cancer
Prior art date
Application number
PCT/US2004/016455
Other languages
French (fr)
Other versions
WO2004110361A2 (en
Inventor
Hong Ji Zhong
Zhi-Ying Chen
Original Assignee
Hong Ji Zhong
Zhi-Ying Chen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hong Ji Zhong, Zhi-Ying Chen filed Critical Hong Ji Zhong
Publication of WO2004110361A2 publication Critical patent/WO2004110361A2/en
Publication of WO2004110361A3 publication Critical patent/WO2004110361A3/en
Priority to US11/283,468 priority Critical patent/US20060079463A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention is directed to anti-cancer compositions comprising methenamine or its derivatives or conjugates, and to use of such methenamine containing compositions to treat cancer. Figure 1 shows methenamine and its hydrolysis in an acid pH.
PCT/US2004/016455 2003-05-20 2004-05-20 Anticancer compositions comprising methenamine WO2004110361A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/283,468 US20060079463A1 (en) 2003-05-20 2005-11-18 Anticancer compositions comprising methenamine

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47196603P 2003-05-20 2003-05-20
US60/471,966 2003-05-20

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/283,468 Continuation-In-Part US20060079463A1 (en) 2003-05-20 2005-11-18 Anticancer compositions comprising methenamine

Publications (2)

Publication Number Publication Date
WO2004110361A2 WO2004110361A2 (en) 2004-12-23
WO2004110361A3 true WO2004110361A3 (en) 2005-04-21

Family

ID=33551436

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/016455 WO2004110361A2 (en) 2003-05-20 2004-05-20 Anticancer compositions comprising methenamine

Country Status (2)

Country Link
CN (1) CN100455289C (en)
WO (1) WO2004110361A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2319491C1 (en) * 2006-07-12 2008-03-20 Бадулин Николай Александрович Antitumor, antibacterial and antiviral pharmaceutical composition (its variants)
EP4212149A1 (en) 2022-01-18 2023-07-19 Rijksuniversiteit Groningen Oral dosage forms of acid-labile salt and methods and uses related thereto

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPR059400A0 (en) * 2000-10-06 2000-11-02 Bar-Ilan University Formaldehyde-releasing prodrugs

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE CAPLUS [online] HINMAN F.: "An experimental study of the antiseptic value in the urine of the internal use of hexamethylenetetramine", XP002985093, accession no. STN Database accession no. 1914:971 *
DATABASE MEDLINE [online] DZHIOEV F.K.: "Prevention using ascorbic acid, hexamethylenetetramine and sodium metabisulfite of the blastomogenic effect caused by the combined administration into the stomach of mice of sodium nitrite with methylurea or with aminopyrine", XP002985094, accession no. STN Database accession no. NLM3201774 *
JAMA, vol. 61, 1914, pages 1601 - 1605 *
VOPROSY ONKOLOGII, vol. 34, no. 11, 1988, pages 1369 - 1373 *

Also Published As

Publication number Publication date
CN1791413A (en) 2006-06-21
WO2004110361A2 (en) 2004-12-23
CN100455289C (en) 2009-01-28

Similar Documents

Publication Publication Date Title
WO2006091720A3 (en) Compositions and methods for targeted delivery of immune response modifiers
DK1556058T3 (en) Pharmaceutical compositions comprising oestetrol derivatives for use in cancer therapy
TNSN05254A1 (en) Derivatives of 2-acylamino-4-phenylthiazole, preparation method thereof and application of same in therapeutics
WO2001091798A3 (en) Tumor activated prodrug compounds
WO2006113483A3 (en) Methods and compositions for treating or preventing cancer
WO2004018000A3 (en) Compositions and methods for treating cancer using maytansinoid cd44 antibody immonoconjugates and chemotherapeutic agents
WO2004103301A3 (en) Synergistic treatment of cancer using immunomers in conjunction with chemotherapeutic agents
WO2002102299A3 (en) Methods and pharmaceutical compositions for immune deception, particularly useful in the treatment of cancer
IL172364A (en) Factor vii or viia gla domain variants
WO2005046722A3 (en) Carbohydrate antigen-nanoparticle conjugates and uses thereof as antimetastatic agents in treating cancer
IL172773A (en) Formulations for the treatment of arthritis conditions
AU2001282399A1 (en) Resorcinol derivatives
NO20050640L (en) Ruthenium anticancer complexes
WO2003106384A3 (en) Novel boronic chalcone derivatives and uses thereof
AU2158601A (en) Antiviral agent for use in treatment of cancer
WO2002102306A3 (en) Methods and compositions for inhibiting, preventing, or reducing tumor cell growth in patients resistant to the antineoplastic effects of antiestrogen therapy
WO2003053180A3 (en) Undergarments containing active substances
EP1635764A4 (en) Conjugate for the specific targeting of anticancer agents to cancer cells and production thereof
WO2004058158A3 (en) Treatment of metastatic cancer with the b-subunit of shiga toxin
WO2003039453A3 (en) Novel benzoyl peroxide compositions for the treatment of dermatological disorders and methods for their use
WO2002011747A3 (en) Transglutaminase for inhibiting angiogenesis
WO2005000204A3 (en) Pancreatic cancer treatment
WO2005079471A3 (en) Cytotoxin compound and method of isolation
WO2003007900A3 (en) Skin treatment
WO2005041881A8 (en) Taxoid-fatty acid conjugates and pharmaceutical compositions thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 11283468

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 20048137460

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 11283468

Country of ref document: US

122 Ep: pct application non-entry in european phase